KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exelixis (EXEL) Cash & Equivalents (2016 - 2026)

Exelixis has reported Cash & Equivalents over the past 17 years, most recently at $482.5 million for Q1 2026.

  • For Q1 2026, Cash & Equivalents rose 121.96% year-over-year to $482.5 million; the TTM value through Jan 2026 reached $482.5 million, up 121.96%, while the annual FY2026 figure was $482.5 million, 121.96% up from the prior year.
  • Cash & Equivalents for Q1 2026 was $482.5 million at Exelixis, up from $376.3 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $723.3 million in Q2 2022 and troughed at $164.4 million in Q3 2025.
  • A 5-year average of $395.8 million and a median of $386.6 million in 2023 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: tumbled 57.27% in 2024 and later skyrocketed 121.96% in 2026.
  • Year by year, Cash & Equivalents stood at $501.2 million in 2022, then plummeted by 47.53% to $263.0 million in 2023, then decreased by 1.77% to $258.3 million in 2024, then skyrocketed by 45.66% to $376.3 million in 2025, then rose by 28.22% to $482.5 million in 2026.
  • Business Quant data shows Cash & Equivalents for EXEL at $482.5 million in Q1 2026, $376.3 million in Q4 2025, and $164.4 million in Q3 2025.